Nasal potential difference measurements in patients with atypical cystic fibrosis

European Respiratory Journal

Volumn 17, Issue 6, 2001, Pages 1208-1215

  Wilschanski, M ^a   Famini, H ^a   Strauss Liviatan, N ^a   Rivlin, J ^a   Blau, H ^a   Bibi, H ^a   Bentur, L ^a   Yahav, Y ^a   Springer, H ^a   Kramer, M R ^a   Klar, A ^a   LLani, A ^a   Kerem, B ^a   Kerem, E ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Atypical phenotype; Cystic fibrosis; Genotype phenotype; Nasal potential difference

Indexed keywords

AMILORIDE; CHLORIDE; ISOPRENALINE; SODIUM ION; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; ARTICLE; CALCULATION; CHILD; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE CLASSIFICATION; EVALUATION; FEMALE; GENE MUTATION; HUMAN; ION TRANSPORT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MODEL; NOSE; PARAMETER; PHENOTYPE; POTENTIAL DIFFERENCE; PREDICTION; PRIORITY JOURNAL; SWEAT TEST;

ADOLESCENT; ADULT; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENOTYPE; HUMANS; MALE; MEMBRANE POTENTIALS; NASAL MUCOSA; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 17844376483     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.00092501     Document Type: Article

References (44)

1. Cystic fibrosis
2. Current concepts: The diagnosis of cystic fibrosis
3. The diagnosis of cystic fibrosis: A consensus statement
4. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis
5. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations
6. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C- > T mutation
7. CFTR mutations in severe nasal polypsis
8. Genetic influences in the formation of nasal polyps
9. Cystic fibrosis presenting with sinus disease in children
10. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis
11. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis
12. Mutations in the cystic fibrosis gene in patients with congenital bilateral absence of the vas deferens
13. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis
14. CFTR mutations in adults with disseminated bronchiectasis
15. Abnormal distribution of cystic fibrosis ΔF508 allele in adults with chronic bronchial hypersecretion
16. Sweat chloride and ΔF508 mutation in chronic bronchitis or bronchiectasis
17. In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis
18. A test for concentration of electroytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis
19. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations
20. Mild course of cystic fibrosis in an adult with the D1152H mutation
21. A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype
22. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel
23. The molecular basis of partial penetrance of splice mutations in cystic fibrosis
24. Similar levels of mRNA from the W1282X and the ΔF508 cystic fibrosis alleles in nasal epithelial cells
25. Screening for five mutations detects 97% of cystic fibrosis chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population
26. In vivo measurements of ion transport in long-living mice
27. Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF mice
28. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
29. A pilot clinical trial of oral sodium-4-phenylbutyrate in ΔF508 homozygous cystic fibrosis patients
30. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane regulator to the nasal epithelium of patients with cystic fibrosis
31. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo
32. Direct activation of cystic fibrosis transmembrane conductance regulator (CFTR) by the alkylxanthine 8-cyclopentyl-1 3-dipropylxanthine (CPX) and 1,3-diallylcyclohexa manthine (DAX)
33. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium
34. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo controlled trial
35. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR
36. Nasal potential difference in congenital bilateral absence of the vas deferens
37. Nasal potential difference in cystic fibrosis patients presenting borderline sweat test
38. Respiratory epithelial ion transport in patients with disseminated bronchiectasis
39. Uncertainty in the diagnosis of cystic fibrosis: Possible role of in vivo nasal potential difference measurements
40. Lung disease associated with the IVS8 5T allele of the CFTR gene
41. Increased frequency of cystic fibrosis ΔF508 mutation in bronchiectasis associated with rheumatoid arthritis
42. Missense mutations in the cystic fibrosis gene in adult patients with asthma
43. Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma